SCHEMBL4848499

SCHEMBL4848499

CNC(=O)[C@H]1CN2C(=O)N(c3cc(Cl)cc(Cl)c3)C(=O)[C@]2(Cc2ccc(OC(F)(F)F)cc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.42
METAP2 P50579 2/20 0.39
HTR2C P28335 1/20 0.37
GCGR P47871 4/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HCRTR1 O43613 3/20 0.35
HCRTR2 O43614 3/20 0.35
EPHX2 P34913 1/20 0.34
KCNH2 Q12809 1/20 0.34
SCN5A Q14524 1/20 0.34
ITGB2 P05107 1/20 0.34
ICAM1 P05362 1/20 0.34
ITGAL P20701 1/20 0.34
TEAD1 P28347 1/20 0.34
CHRNA7 P36544 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34
MAPT P10636 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4841580 0.89 METAP2 (0.39) SCN9AMETAP2HTR2CGCGRLMNA
SCHEMBL4848356 0.88 METAP2 (0.37) SCN9AMETAP2HTR2CGCGRLMNA
SCHEMBL4847278 0.88 SCN9A (0.38) SCN9AMETAP2HTR2CLMNANPSR1
SCHEMBL14254856 0.87 METAP2 (0.39) SCN9AMETAP2HTR2CHCRTR1HCRTR2
SCHEMBL4841746 0.87 METAP2 (0.39) SCN9AMETAP2HTR2CHCRTR1HCRTR2
SCHEMBL4844861 0.85 METAP2 (0.39) SCN9AMETAP2GCGRHCRTR1HCRTR2
SCHEMBL4885451 0.84 EPHX2 (0.38) SCN9AMETAP2EPHX2SCN5A
SCHEMBL14254846 0.83 GCGR (0.35) METAP2HTR2CGCGRLMNAHCRTR1
SCHEMBL6489587 0.83 METAP2 (0.37) SCN9AMETAP2HCRTR1HCRTR2ITGB2
SCHEMBL6490093 0.82 METAP2 (0.37) SCN9AMETAP2GCGRHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897225-B1 Inhibitors of αLβ2 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2005-05-24 US claimed
EP-1307455-B1 INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION TANABE SEIYAKU CO (JP) 2005-04-06 EP claimed
US-7342012-B2 Inhibitors of αLβ2 mediated cell adhesion MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-11 US disclosed
US-20050148602-A1 Inhibitors of alphaLbeta2 mediated cell adhesion TANABE SEIYAKU CO., LTD. 2005-07-07 US disclosed
US-6897225-B1 Inhibitors of αLβ2 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2005-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148602-A1 Inhibitors of alphaLbeta2 mediated cell adhesion ITGB2, ITGA2B, ITGB1 SCN9A 143/4885METAP2 1571/4885HTR2C 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.